Novartis reports positive Phase III trial data for relapsing multiple sclerosis drug remibrutinib
Novartis flagged positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis. Late-breaking trial data will be presented at MSToronto2026 on Oct. 23, positioning the oral BTK inhibitor as a potential new option.